AMENDMENT

Please amend the above-identified application as follows:

In the Claims:

Add new claim 11 as follows.

Claim 1 (previously presented) A compound of Formula I, and pharmaceutically acceptable salts thereof,

Formula 1

wherein:

$$R_1$$
 is -(CR^aR^b)_n-X;

 R^a , R^b are each independently selected from the group consisting of H, C_{1-6} alkyl; each of said C_{1-6} alkyl being optionally substituted with one to six same or different halogen;

X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with a member selected from the group consisting of one to six same or different halogen or hydroxy;

n is 1-6;

R₂ and R₅ are independently halogen or H;

 R_3 and R_4 are each independently selected from the group consisting of H, halogen and C_{1-6} alkyl; said C_{1-6} alkyl can be optionally substituted with one to six same or different halogen;

Q is a member selected from the group consisting of

$$R_{26}$$
 R_{27}
 R_{28}
 R_{28}
 R_{29}

Rh is H or C₁₋₆ alkyl;

 R_{26} is selected from the group consisting of H, halogen, C_{1-6} alkyl; C_{2-6} alkenyl, OR^h and COR^h ; said C_{2-6} alkenyl being optionally substituted with OR^h ;

R₂₇ is H, OR^h or CO₂R^h;

R₂₈ is CO₂R^h; and

R₂₉ is H or halogen.

Claim 2. (cancelled)

Claim 3. (cancelled)

Claim 4. (original) A compound of claim 1 wherein:

Ra and Rb are hydrogen.

Claim 5. (original) A compound of claim 1 wherein:

 R_1 is $-(CH_2)_n$ -X and n is 2-4.

Claim 6. (original) A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.

Claim 7. (previously presented) A compound in claim 1 wherein:

 R_1 is 3-methyl-2-butyl or $-(CH_2)_n$ -X; and wherein n is 2-4.

Claim 8. (original) A compound of claim 1 wherein:

R₂ and R₅ are independently H.

Claim 9. (cancelled)

Claim 10. (previously presented) A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1, 4, 5, 6, 7 or 8, and a pharmaceutically acceptable carrier.

Claim 11. (new) A method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1, 4, 5, 6, 7 or 8.